公开(公告)号：US11919953B2

公开(公告)日：2024-03-05

申请号：US17375958

申请日：2021-07-14

Applicant: AMGEN INC.

Inventor： Sue J. Sohn ,  Marissa Mock ,  Ian Nevin Foltz ,  Agnieszka Kielczewska ,  Kathy Manchulenko ,  Yannick Bulliard ,  Xiaoshan Min

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.

公开(公告)号：US11976103B2

公开(公告)日：2024-05-07

申请号：US17065395

申请日：2020-10-07

Applicant: Amgen Inc.

Inventor： Eric Alan Butz ,  Christy Ann Thomson ,  Marc Alain Gavin ,  Ian Nevin Foltz ,  Dong Xia ,  Dina N. Alcorn ,  Randal Robert Ketchem ,  Ai Ching Lim ,  Kathy Manchulenko ,  Laura Sekirov ,  Kelly Ann Berry ,  Cyr Clovis Chua De Imus ,  Neeraj Jagdish Agrawal ,  Gunasekaran Kannan ,  Li Li

IPC: A61K38/20 ,  A61P37/00 ,  C07K14/55 ,  C07K16/24

CPC classification number: C07K14/55 ,  A61K38/2013 ,  A61P37/00 ,  C07K16/246 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US10851144B2

公开(公告)日：2020-12-01

申请号：US15565376

申请日：2016-05-04

Applicant: AMGEN INC.

Inventor： Eric Alan Butz ,  Christy Ann Thomson ,  Marc Alain Gavin ,  Ian Nevin Foltz ,  Dong Xia ,  Dina N. Alcorn ,  Ai Ching Lim ,  Randal Robert Ketchum ,  Kathy Manchulenko ,  Laura Sekirov ,  Kelly Ann Berry ,  Cyr Clovis Chua De Imus ,  Neeraj Jagdish Agrawal ,  Gunasekaran Kannan ,  Li Li

IPC: C07K14/55 ,  A61P37/00 ,  A61K38/20 ,  C07K16/24

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.